Lung Cancer

In my last post, I described the concept of treating with a targeted therapy like an EGFR tyrosine kinase inhibitor (TKI) or ALK inhibitor at the time of acquired resistance.

Here's the second presentation from our program on "Immunotherapies for Lung Cancer: Can We Deliver on the Promise?".  Our

Here's part 1 of the podcast with Dr. Ramaswamy Govindan from Washington University, in St. Louis, and Dr. Julie Brahmer from Johns Hopkins University in Baltimore, splitting the big topic of new developments in immunotherapy for lung cancer.

  Earlier this week, I provided a brief review of several highlighted posters at ASCO, along with some commentary to place them into context.  These posters represent only preliminary volleys of helpful information, describing findings from retrospective evaluations of outcomes from single institutions.  Nevertheless, they provide a meaningful starting point for what should become a richer conversation as we come to understand how best to use targeted therapies for very targeted populations.

   The main points I covered in my discussion were:

This is the last of six podcasts produced from the two hour program we did in partnership with the LUNGevity Foundation earlier this year in Santa Monica, at the start of the "Targeted Therapies in Lung Cancer" annual meeting.  This activity was comprised of some great panel discussions and brief presentations on tough but timely issues on the subject of "Molecular Markers in Advanced NSCLC: Who to Test and What to Test For?".  It featured guest faculty members Dr. Charlie Rudin from Johns Hopkins University, Dr. Alice Shaw from Massachusetts General Hospital, Dr.

Here are the 5 presentations at ASCO in stage I-III NSCLC and small cell lung cancer that I think are most interesting and relevant.  You'll note that several are "negative" trials -- blockbusters are hard to come by here -- but even trials that tell us what not to do are important.   And there are some hints of new approaches that could improve outcomes for patients.

The annual conference of the American Society of Clinical Oncology in late spring is the biggest event in the cancer world, where more of the big trials are presented than at any other time all year.  In the lung cancer world, it’s looking like this one won’t be a blockbuster but will have some promising and interesting findings to dis

While post-operative chemotherapy for early stage NSCLC is a well-established standard for relatively healthy patients with stage II or higher resected cancers, the question of whether adjuvant chemotherapy is more likely to help or hurt a patient remains more a matter of debate.